Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

  1. Waalewijn, H.
  2. Chan, M.K.
  3. Bollen, P.D.J.
  4. Mujuru, H.A.
  5. Makumbi, S.
  6. Kekitiinwa, A.R.
  7. Kaudha, E.
  8. Sarfati, T.
  9. Musoro, G.
  10. Nanduudu, A.
  11. Lugemwa, A.
  12. Amuge, P.
  13. Moore, C.L.
  14. Rojo, P.
  15. Giaquinto, C.
  16. Colbers, A.
  17. Gibb, D.M.
  18. Ford, D.
  19. Turkova, A.
  20. Burger, D.M.
Journal:
The Lancet HIV

ISSN: 2352-3018

Year of publication: 2022

Volume: 9

Issue: 5

Pages: e341-e352

Type: Article

DOI: 10.1016/S2352-3018(21)00292-7 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals